To complement the insufficient bioavailability of azilsartan, particle size reduction of azilsartan by drowning- out was attempted. By injecting an azilsartan/ethanol solution into the antisolvent of water, two phases of azilsartan, amorphous and crystalline type A, were found along with phase transformation. The crystal size was strongly affected by the operating parameters such as the volume ratio of antisolvent/azilsartan solution, crystallization temperature, and additives. The crystal size decreased upon increasing the antisolvent/azilsartan solution volume ratio and lowering the temperature. Furthermore, addition of carboxylic acids to the antisolvent of water produced nano-meter sized crystals. In particular, 200 nm particles were obtained with acetic acid. An enhancement in the dissolution rate was found for size-reduced azilsartan crystals, especially when the crystals… sizes were in the nanometer range.

Azilsartan Crystal Size Reduction Dissolution Rate Drowning-out Crystallization Phase Transformation

Kurtz TW, Kajiya T, Vasc. Health Risk Manage, 18, 133 (2012)
Blagden N, de Matas M, Gavan PT, York P, Adv. Drug Deliv. Rev., 59(7), 617 (2007)
Noyes AA, Whitney WR, J. Am. Chem. Soc., 19(12), 930 (1897)
Lu T, Sun Y, Ding D, Zhang Q, Fan R, He Z, Wang J, AAPS J., 18(2), 473 (2017)
Tinke AP, Vanhoutte K, De Maesschalck R, Verheyen S, De Winter H, J. Pharm. Biomed. Anal., 39(5), 900 (2005)
Verma S, Gokhale R, Burgess DJ, Int. J. Pharm., 380(1-2), 216 (2009)
Rasenack N, Muller BW, Pharm. Dev. Technol., 9(1), 1 (2004)
Sharma C, Desai MA, Patel SR, Cryst. Res. Technol., 53(3), 180000 (2018)
Jain S, Reddy VA, Arora S, Patel K, Drug Deliv. Transl. Res., 6(5), 498 (2016)
Ma Q, Sun H, Che E, Zheng X, Jiang T, Sun C, Wang S, Int. J. Pharm., 441(1-2), 75 (2013)
Zhang Z, Le Y, Wang J, Zhao H, Chen J, Particuology, 10(4), 462 (2012)
Hancock BC, Zografi G, Pharm. Res., 11, 471 (1994)
Chan HK, Chew NY, Adv. Drug Deliv. Rev., 55, 793 (2003)
Kim WS, Koo KK, Cryst. Growth Des., 19, 1797 (2019)
Reddy AVR, Garaga S, Takshinamoorthy C, Gupta G, Naidu A, Indo Am. J. Pharm. Res., 5(6), 2208 (2015)
Tomlinson E, Int. J. Pharm., 13, 115 (1983)
Tomlinson E, Davis SS, J. Colloid Interface Sci., 76, 563 (1980)
Krug RR, Hunter WG, Grieger RA, J. Phys. Chem., 80, 2341 (1976)
Bustamante P, Romero S, Pena A, Escalera B, Reillo A, J. Pharm. Sci., 87, 1590 (1998)
Rouw AC, Somsen G, J. Solution Chem., 10, 533 (1981)
Heuvelsland WJM, de Visser C, Somsen G, J. Phys. Chem., 82, 29 (1978)
Martinez F, Pena MA, Bustamante P, Fluid Phase Equilib., 308(1-2), 98 (2011)
Tung HH, Paul EL, Midler M, McCauley JA, Crystallization of organic compounds: an industrial perspective, Wiley, NewYork (2009).
Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U, Langmuir, 22(3), 906 (2006)
Erdemir D, Lee AY, Myerson AS, Accounts Chem. Res., 42(5), 621 (2009)
Maher A, Croker DM, Rasmuson AC, Hodnett BK, Cryst. Growth Des., 12(12), 6151 (2012)
Kim JW, Kim JK, Kim HS, Koo KK, Cryst. Growth Des., 9(6), 2700 (2009)
Kakran M, Sahoo NG, Tan IL, Li L, J. Nanopart. Res., 14(3), 757 (2012)
Du W, Yin QX, Hao HX, Bao Y, Zhang X, Huang JT, Li X, Xie C, Gong JB, Ind. Eng. Chem. Res., 53(14), 5652 (2014)
Gu CH, Young Y, J. Pharm. Sci., 90(11), 1878 (2001)
Rodriguez-hornedo N, Murphy D, J. Pharm. Sci., 88(7), 651 (1999)
Zhang XR, Zhang L, J. Mol. Struct., 1137, 320 (2017)